ABBOTT PARK, IL — July 3, 2002 —
Abbott Laboratories announced that Europe’s Committee for Proprietary Medicinal Products (CPMP) issued a positive opinion reaffirming the favorable risk/benefit profile of sibutramine HCl monohydrate capsules for the treatment of obesity.
The positive opinion that resulted from this review is consistent with the conclusions of Abbott, and leading experts in the treatment of obesity: sibutramine, marketed in the United States as Meridia® and in many other countries as Reductil®, is safe and effective.
“As a physician who treats obese patients, the conclusion that sibutramine is safe and effective for the treatment of obesity is consistent with my own experience using sibutramine in treating this disease,” said Dr. Stephan Rossner, head of the Obesity Unit, Huddinge University Hospital, Stockholm, Sweden.
“Obesity is an international epidemic. It contributes significantly to the onset of other serious medical conditions such as diabetes, cardiovascular diseases, cancer and respiratory conditions. Sibutramine, when used in combination with diet and exercise, is an important tool in my practice that helps treat obesity.” Eugene Sun, M.D., Abbott’s divisional vice president, Global Pharmaceutical Development, added, “The CPMP’s conclusion should reassure physicians and patients who depend on sibutramine to treat obesity that the product is safe when used as directed.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!